A Phase 3 Open-Label Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Push Compared with Intravenous Amivantamab or Subcutaneous Amivantamab Administered via On Body Delivery System in Patients with EGFR-Mutated Advanced or Metastatic Non-Small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy.

Brief description of study

You can participate in this study if you are diagnosed with advanced lung cancer. The purpose of this study is to know the efficacy and safety of study drug (Lazertinib) in combination with the study drug (Amivantamab) by using different mode of administrations. The study is also being done to learn more about how the study drug is absorbed (taken up in the body), metabolized (broken-down by the body), distributed (circulated in the body), and eliminated (passed out of the body) when administered using different mode of administrations. The patients will be monitored and taken care of while on this medication during the entire study period.

Clinical Study Identifier: s22-00863

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.